Selpercatinib (Retevmo) structure · RET / MET / NTRK TKI

Selpercatinib (Retevmo) 2D structure

Role: Drug
Family: RET / MET / NTRK oncogene TKI series
Mechanism class: RET / MET / NTRK TKI
Parent scaffold: Multi-kinase hinge core

Structure source: Catalog seed

How similarity is calculated

Hand-written analysis

Mechanism

셀퍼카티닙은 RET 선택 TKI입니다. 융합·돌연변이 RET 종양(폐·갑상선)에 쓰입니다. 멀티키나제 RET 약보다 off-target이 적게 설계됩니다.

Medicinal chemistry

선택적 RET 힌지 바인더입니다. 프랄세티닙과 같은 층, 다른 치환입니다.

Indication · context

RET+ NSCLC·갑상선. /class 온코진 TKI 허브에서 MET·NTRK와 나눕니다.

SMILES

CC1=CC(=C(C=C1)C2=NC(=NC(=C2)N3CCN(CC3)C)NC4=CC=C(C=C4)OC)C

Related compounds

External IDs · BioMoa

PubChem 검색 ChEMBL 검색 PubChem (SMILES)BioMoa · RET / Retevmo BioMoa bridge Open on the family map Flow Structure table Mechanism class

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Methodology

Selpercatinib (Retevmo) structure · mechanism